Canaccord Genuity Group Reiterates “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Canaccord Genuity Group reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a $14.00 target price on the stock.

A number of other brokerages have also recently commented on VYGR. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Finally, Wedbush lowered their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Voyager Therapeutics Stock Down 7.4 %

Shares of NASDAQ VYGR traded down $0.46 during mid-day trading on Thursday, reaching $5.76. 403,619 shares of the company were exchanged, compared to its average volume of 641,439. The company’s 50 day moving average price is $6.63 and its 200 day moving average price is $7.52. Voyager Therapeutics has a 52 week low of $5.67 and a 52 week high of $11.72. The stock has a market capitalization of $314.09 million, a PE ratio of 8.11 and a beta of 0.89.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.53% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently modified their holdings of VYGR. Great Point Partners LLC acquired a new position in shares of Voyager Therapeutics in the 2nd quarter worth approximately $12,668,000. Erste Asset Management GmbH acquired a new position in Voyager Therapeutics during the third quarter valued at approximately $6,192,000. Farallon Capital Management LLC lifted its position in shares of Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after acquiring an additional 702,030 shares during the period. Finally, Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.